Phase II study of mipsagargin (g-202), a psma-activated prodrug targeting the tumor endothelium, in adult patients with recurrent or progressive glioblastoma

Authors
Category Primary study
JournalNeuro-Oncology
Year 2015
This article has no abstract
Epistemonikos ID: a8e99d2656764e51ef3f1404701a227e65d1b2bd
First added on: Feb 07, 2025